Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update
- PMID: 40477045
- PMCID: PMC7295303
- DOI: 10.1055/s-0040-1712547
Emerging Treatment and Prevention Strategies against COVID-19: A Brief Update
Abstract
Patients with novel coronavirus disease 2019 (COVID-19) are at significantly increased risk for mortality and morbidity. Current management remains supportive care, ranging from symptomatic outpatient management to full-intensive care support, including intravenous fluids, invasive, and non-invasive oxygen supplementation. In patients with septic shock, treatment with antibiotics and vasopressors are recommended to keep mean arterial pressure (MAP) ≥ 65 mm Hg and lactate < 2 mmol/L. Because of the lack of effectiveness and possible adverse effects, routine corticosteroids should be avoided unless they are indicated for another reason (exacerbation of asthma or chronic obstructive pulmonary disease [COPD], and septic shock in whom fluids and vasopressors do not restore hemodynamic stability). There is currently no sufficient evidence of efficacy of hydroxychloroquine/chloroquine, remdesivir, and other antivirals in the treatment or prevention of COVID-19. Limited evidence shows that COVID-19 convalescent plasma can be used as a treatment of COVID-19 without the occurrence of severe adverse events. Drug regulatory agencies granted an emergency-use authorization of chloroquine/hydroxychloroquine and remdesivir to treat patients when a clinical trial is not available or participation is not feasible. Chloroquine and hydroxychloroquine are associated with QT interval prolongation and life-threatening cardiac arrhythmia in patients with pre-existing cardiovascular disease. Guidelines are issued for use of convalescent plasma in patients with serious or immediately life-threatening COVID-19. Data from several ongoing randomized controlled trials will provide further evidence regarding the safety and efficacy of these drugs for the treatment of COVID-19.
Keywords: World Health Organization; chloroquine; convalescent plasma; hydroxychloroquine; novel coronavirus disease 2019; remdesivir; severe acute respiratory syndrome-coronavirus-2; vaccines.
Conflict of interest statement
Conflict of Interest None declared.
References
-
- World Health Organization. Country & Technical Guidance - Coronavirus disease (COVID-19). Available at:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technica... Accessed April 19, 2020
-
- Gautret P, Lagier J C, Parola Pet al.Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study Travel Med Infect Dis 2020(e-pub ahead of print)10.1016/j.tmaid.2020.101663 - DOI - PMC - PubMed
-
- European Medicines AgencySummary on compassionate use. Available at: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-r.... Accessed April 19, 2020)
Publication types
LinkOut - more resources
Full Text Sources